Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 2/20 | 0.34 |
| ▸ | IMPDH2 | P12268 | 5/20 | 0.32 |
| ▸ | IMPDH1 | P20839 | 1/20 | 0.32 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | TAS1R3 | Q7RTX0 | 2/20 | 0.31 |
| ▸ | TAS1R1 | Q7RTX1 | 2/20 | 0.31 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25808153 | 0.83 | IMPDH2 (0.35) | HPGDIMPDH2IMPDH1PAX8TAS1R3 | |
| SCHEMBL22577502 | 0.83 | TYMP (0.46) | HPGDIMPDH2IMPDH1TAS1R3TAS1R1 | |
| SCHEMBL22577573 | 0.77 | KDM4E (0.41) | KDM4ETAS1R3TAS1R1 | |
| SCHEMBL14156808 | 0.76 | HPGD (0.57) | HPGDPAX8ADORA1 | |
| SCHEMBL22577600 | 0.75 | TYMP (0.44) | — | |
| SCHEMBL22577504 | 0.73 | TYMP (0.54) | IMPDH2IMPDH1TAS1R3TAS1R1ADORA1 | |
| SCHEMBL25808149 | 0.71 | HPGD (0.46) | HPGDIMPDH2IMPDH1PAX8TAS1R3 | |
| SCHEMBL14156807 | 0.71 | ALDH1A1 (0.54) | HPGDKDM4ETAS1R3TAS1R1 | |
| SCHEMBL22577556 | 0.67 | — | — | |
| SCHEMBL18992534 | 0.67 | KDM4E (0.52) | HPGDIMPDH2IMPDH1KDM4ETAS1R3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11685761-B2 | Cyclic di-nucleotide compounds as sting agonists | MERCK SHARP & DOHME LLC (US) | 2023-06-27 | — | — | US | disclosed |
| US-20210206796-A1 | CYCLIC DI-NUCLEOTIDE COMPOUNDS AS STING AGONISTS | MERCK SHARP & DOHME CORP. (US) | 2021-07-08 | — | — | US | disclosed |
| EP-3727401-A1 | CYCLIC DI-NUCLEOTIDE COMPOUNDS AS STING AGONISTS | MERCK SHARP & DOHME CORP. (US) | 2020-10-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210206796-A1 | CYCLIC DI-NUCLEOTIDE COMPOUNDS AS STING AGONISTS | STING1, CGAS, IFNAR1 | HPGD 1717/4885IMPDH2 1168/4885IMPDH1 596/4885 |
| US-11685761-B2 | Cyclic di-nucleotide compounds as sting agonists | STING1, CGAS, IFNAR1 | HPGD 1650/4885IMPDH2 1125/4885IMPDH1 579/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.